l General Information |
Product Name | Sorafenib |
General description | Sorafenib is a synthetic compound targeting growth signaling and angiogenesis. |
Synonym | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; Nexavar; BAY 43-9006; |
Purity | ≥99%(HPLC) | CAS Number | 284461-73-0 |
Formula | C21H16ClF3N4O3 | Molecular Weight | 464.829 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to pale brown powder |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Sorafenib is a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. |
Application | 1.Protein Kinase Inhibitors 2.Antineoplastic Agents |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
